lactic acid has been researched along with alprostadil in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kamei, T; Kayashima, K; Konomi, K; Matsuo, K; Ueda, Y | 1 |
| Amendt, K; Hild, R; Rexroth, W; Römmele, U; Stein, U; Wagner, E | 1 |
| Catafau, JR; Gimeno, AL; Gimeno, MA; Gomez, G; Gonzalez, ET; Jawerbaum, A; Rodriguez, RR | 1 |
| Groeneveld, AB; Nauta, JJ; Thijs, LG; Vermeij, CG | 1 |
| Arai, T; Tayasu, E | 1 |
| Akamatsu, K; Hashida, M; Nishikawa, M; Takakura, Y; Yamashita, F | 1 |
| Akamatsu, K; Hashida, M; Nishikawa, M; Takakura, Y; Yamashita, F; Yoshikawa, H | 1 |
| Chang, K; Hanaoka, K; Hayashida, M; Makuuchi, M; Orii, R; Sugawara, Y; Takayama, T; Yamada, Y | 1 |
| Arosarena, OA; Collins, WL | 1 |
| Al-Badawi, H; Patton, GM; Peterson, B; Russo, AL; Soler, H; Watkins, MT | 1 |
| Das, UN; Sailaja Devi, MM | 1 |
| Higaki, M; Igarashi, R; Ishihara, T; Maeda, T; Mizushima, T; Mizushima, Y; Nishimura, F; Ogawa, H; Okamoto, Y; Otsuka, M; Sakamoto, H; Takasaki, N; Takeda, M; Takenaga, M; Tanaka, K; Yamakawa, N; Yamashita, T; Yuki, K | 1 |
| Arai, Y; Bir, SC; Esaki, J; Huang, Y; Ikeda, T; Kanaji, T; Marui, A; Sakaguchi, H; Sakata, R; Tsubota, H | 1 |
| Aoyagi, S; Okazaki, T | 1 |
| Ahsan, F; Gupta, V; Rawat, A | 1 |
| Ahsan, F; Gupta, V | 1 |
| Ahsan, F; Davis, M; Gupta, V; Hope-Weeks, LJ | 1 |
| Ahsan, F; Gupta, N; Gupta, V; Komatsu, M; McMurtry, IF; Mehvar, R; Nozik-Grayck, E; Oka, M; Shaik, IH | 1 |
| Lu, J; Ma, J; Qing, E; Wang, C; Zhao, L; Zhao, W | 1 |
2 trial(s) available for lactic acid and alprostadil
| Article | Year |
|---|---|
Effects of amrinone on ischaemia-reperfusion injury in cirrhotic patients undergoing hepatectomy: a comparative study with prostaglandin E1.
Topics: Aged; Alprostadil; Amrinone; Analysis of Variance; Female; Hepatectomy; Humans; Indocyanine Green; Lactic Acid; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Phosphodiesterase Inhibitors; Platelet Aggregation Inhibitors; Reperfusion Injury | 2000 |
Prostaglandin E1 increases the blood flow rate of saphenous vein grafts in patients undergoing off-pump coronary artery bypass grafting.
Topics: Adult; Aged; Alprostadil; Angina, Stable; Arterial Pressure; Cardiac Output; Coronary Artery Bypass, Off-Pump; Coronary Circulation; Critical Care; Double-Blind Method; Female; Hemodynamics; Humans; Infusions, Intravenous; Lactic Acid; Male; Middle Aged; Oxygen Consumption; Prospective Studies; Regional Blood Flow; Saphenous Vein; Vasodilator Agents | 2013 |
18 other study(ies) available for lactic acid and alprostadil
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Protective effect of prostaglandin E1 (PGE1) on energy metabolism and reticuloendothelial function in the ischemically damaged canine liver.
Topics: Adenosine Triphosphate; Alprostadil; Animals; Dogs; Energy Metabolism; Ischemia; Kupffer Cells; Lactates; Lactic Acid; Liver; Phagocytosis; Time Factors | 1989 |
[Effects of prostaglandin El on hemodynamics and metabolism of the extremities in healthy humans and patients with stage III and IV arterial occlusive disease].
Topics: Adult; Alprostadil; Arterial Occlusive Diseases; Diabetic Angiopathies; Energy Metabolism; Hemodynamics; Humans; Lactates; Lactic Acid; Leg; Male; Muscles; Vascular Resistance | 1985 |
Glucose, glycogen and triglyceride metabolism, as well as prostaglandin production in uterine strips and in embryos from diabetic pregnant rats. Influences of the presence of substrate in the incubation medium.
Topics: Alprostadil; Animals; Culture Techniques; Diabetes Mellitus, Experimental; Dinoprostone; Female; Fetus; Glucose; Glycogen; Indomethacin; Lactates; Lactic Acid; Pregnancy; Pregnancy in Diabetics; Prostaglandins; Rats; Rats, Wistar; Triglycerides; Uterine Contraction; Uterus | 1993 |
Vasodilating prostaglandin E1 decreases critical oxygen delivery by increasing critical oxygen extraction in anesthetized pigs.
Topics: Alprostadil; Anesthesia; Animals; Cardiac Output; Hemodynamics; Infections; Lactates; Lactic Acid; Male; Oxygen Consumption; Positive-Pressure Respiration; Respiratory Distress Syndrome; Swine; Vasodilation | 1993 |
[Prevention of postoperative liver dysfunction by intraoperative administration of PGE1 and dopamine].
Topics: Alprostadil; Anesthesia, Epidural; Dopamine; Drug Therapy, Combination; Hepatectomy; Humans; Intraoperative Period; Ketone Bodies; Lactic Acid; Liver Circulation; Liver Diseases; Postoperative Complications; Stress, Physiological; Time Factors | 1996 |
Design of polymeric prodrugs of prostaglandin E(1) having galactose residue for hepatocyte targeting.
Topics: Alprostadil; Animals; Biodegradation, Environmental; Carbohydrate Sequence; Chemical Phenomena; Chemistry, Physical; Drug Design; Galactose; Glycosylation; Lactic Acid; Liver; Mice; Molecular Sequence Data; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polylysine; Polymers; Prodrugs; Solubility; Water | 1999 |
Design of polymeric prodrugs of PGE1 for cell-specific hepatic targeting.
Topics: Acute Disease; Alprostadil; Animals; Biological Availability; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Drug Design; Indium Radioisotopes; Lactic Acid; Liver; Mice; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polylysine; Polymers; Prodrugs; Tissue Distribution | 2000 |
Defect repair in the rat mandible with bone morphogenic protein 5 and prostaglandin E1.
Topics: Alprostadil; Animals; Biocompatible Materials; Bone Morphogenetic Protein 5; Bone Morphogenetic Proteins; Collagen; Disease Models, Animal; Drug Carriers; Drug Therapy, Combination; Durapatite; Growth Substances; Lactic Acid; Male; Mandibular Injuries; Osteogenesis; Polyesters; Polymers; Prospective Studies; Rats; Rats, Sprague-Dawley | 2003 |
Human microvascular endothelial cell prostaglandin E1 synthesis during in vitro ischemia-reperfusion.
Topics: Alprostadil; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Dinoprostone; Endothelium, Vascular; Humans; Isoenzymes; Lactic Acid; Membrane Proteins; Microcirculation; Prostaglandin-Endoperoxide Synthases; Reperfusion Injury; RNA, Messenger; Skin | 2004 |
Effect of prostaglandins against alloxan-induced diabetes mellitus.
Topics: Alloxan; Alprostadil; Animals; Antioxidants; Blood Glucose; Body Weight; Catalase; Ceruloplasmin; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dinoprostone; Erythrocytes; Glutathione Peroxidase; Glutathione Transferase; Injections, Intraperitoneal; Insulin; Lactic Acid; Lipid Peroxides; Male; Malondialdehyde; Nitric Oxide; Pancreas; Prostaglandins; Prostaglandins F; Rats; Rats, Wistar; Superoxide Dismutase; Thromboxane B2 | 2006 |
Synthesis of prostaglandin E(1) phosphate derivatives and their encapsulation in biodegradable nanoparticles.
Topics: Alprostadil; Animals; Drug Carriers; Humans; Hydrolysis; Lactic Acid; Nanoparticles; Particle Size; Phosphates; Platelet Aggregation; Polyesters; Polyethylene Glycols; Polymers; Prodrugs; Rats; Rats, Wistar; Regional Blood Flow; Serum; Skin; Zinc | 2009 |
Local sustained release of prostaglandin E1 induces neovascularization in murine hindlimb ischemia.
Topics: Alprostadil; Animals; Blood Vessels; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Hindlimb; Ischemia; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Microspheres; Neovascularization, Physiologic; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2009 |
How do poly lactide-co-glycolide microspheres for prostaglandin E1 operate in ischemic tissue? Local sustained release of prostaglandin E1 induces neovascularization in murine hindlimb ischemia.
Topics: Alprostadil; Animals; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Hindlimb; Ischemia; Lactic Acid; Mice; Microspheres; Neovascularization, Physiologic; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2009 |
Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension.
Topics: Administration, Inhalation; Alprostadil; Animals; Bronchoalveolar Lavage; Cell Line; Cell Survival; Epithelial Cells; Humans; Hypertension, Pulmonary; Lactic Acid; Lung; Male; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polyvinyl Alcohol; Rats; Rats, Sprague-Dawley | 2010 |
Influence of PEI as a core modifying agent on PLGA microspheres of PGE₁, a pulmonary selective vasodilator.
Topics: Administration, Inhalation; Alprostadil; Animals; Bronchoalveolar Lavage Fluid; Cell Survival; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Excipients; Extracellular Fluid; Lactic Acid; Lung; Male; Microspheres; Particle Size; Polyethyleneimine; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polyvinyl Alcohol; Rats; Rats, Sprague-Dawley; Surface Properties; Vasodilator Agents | 2011 |
PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Alprostadil; Animals; Antihypertensive Agents; beta-Cyclodextrins; Cell Line; Cell Survival; Delayed-Action Preparations; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Infusion Pumps; Lactic Acid; Male; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley | 2011 |
Inhaled PLGA particles of prostaglandin E₁ ameliorate symptoms and progression of pulmonary hypertension at a reduced dosing frequency.
Topics: Administration, Inhalation; Alprostadil; Animals; Delayed-Action Preparations; Disease Models, Animal; Disease Progression; Drug Carriers; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lactic Acid; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Vasodilator Agents; von Willebrand Factor | 2013 |